Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | PKLR | P30613 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18184512 | 0.81 | PKM (0.55) | PKMPKLRCYP2A6PRKCITHRB | |
| SCHEMBL8761290 | 0.79 | PRKCI (0.55) | PKMPKLRCYP2A6PRKCITHRB | |
| SCHEMBL516947 | 0.79 | PKM (0.54) | PKMPKLRCYP2A6PRKCITHRB | |
| SCHEMBL4617771 | 0.79 | PKM (0.54) | PKMPKLRCYP2A6PRKCITHRB | |
| Hydrochloric Acid SCHEMBL27788112 | 0.78 | PKM (0.52) | PKMPKLRCYP2A6PRKCITHRB | |
| SCHEMBL10153740 | 0.77 | PKM (0.62) | PKMPKLRCYP2A6PRKCITHRB | |
| SCHEMBL13131546 | 0.77 | PKM (0.51) | PKMPKLRCYP2A6PRKCITHRB | |
| SCHEMBL12418684 | 0.76 | ABL1 (0.50) | PKMHTR2CLMNA | |
| SCHEMBL13197241 | 0.74 | ABL1 (0.46) | PKMHTR2CLMNA | |
| SCHEMBL8761234 | 0.72 | PKM (0.60) | PKMPKLRCYP2A6THRBSIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411426-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-12-29 | — | — | US | disclosed |
| US-11040976-B2 | Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190016723-A9 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-01-17 | — | — | US | disclosed |
| US-20180194768-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN DEGRADING ENZYME (IDE) AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180194768-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN DEGRADING ENZYME (IDE) AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194768-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN DEGRADING ENZYME (IDE) AND USES THEREOF | IDE, SI, GPR119 | PKM 545/4885PKLR 828/4885CYP2A6 234/4885 |
| US-20220411426-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | IDE, SI, GPR119 | PKM 551/4885PKLR 757/4885CYP2A6 227/4885 |
| US-20190016723-A9 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | IDE, SI, GPR119 | PKM 591/4885PKLR 828/4885CYP2A6 233/4885 |
| US-11040976-B2 | Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof | IDE, SI, GPR119 | PKM 591/4885PKLR 828/4885CYP2A6 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.